SELLAS Life Sciences ($SLS): What Does Sentiment Say Ahead of REGAL?

*Intraday reference at the capture time; not a target or valuation estimate.

Every Merlintrader report is posted to @merlintraderpub_com on Telegram the moment it goes live.

The broad public mood around SELLAS Life Sciences ($SLS) is still bullish in headcount, but the distribution of influence is much less one-sided. StockTwits and the dedicated Reddit community remain strongly long-biased. Seeking Alpha is more mixed and analytical. On X, a relatively small cluster of skeptical biotech voices can reach audiences much larger than their numerical presence suggests. Reported short interest remains structurally high, which adds a second, capital-based measure of disagreement.

1. What changed when we expanded the sentiment check

The original September 2 snapshot already showed a sharp split: StockTwits tagged messages were overwhelmingly bullish while X hosted a smaller but more visible skeptical cluster. The expanded review adds several layers that make the picture more useful.

A September 2 company release also gave the bullish narrative a fresh non-REGAL leg: SELLAS announced that three SLS009 (tambiciclib) abstracts were accepted for poster presentation at the AACR Conference on Pancreatic Cancer, based on preclinical patient-derived KRAS-mutant organoid work. It is relevant to attention around the pipeline, but it is not human efficacy evidence.

Source weighting

2. StockTwits: still bullish, no longer euphoric

At the latest capture, the canonical StockTwits score for SLS was 56 / Bullish. The tagged-message split was far more extreme: 90.72% bullish versus 9.28% bearish, with 61,705 watchers. Message-volume intensity was 54 / Normal.

The gap matters. Self-labeled posts are overwhelmingly long-biased, while the platform’s normalized score says the emotional temperature has cooled significantly from the late-August high. This is best described as a cooldown in conviction intensity, not a reversal into bearish territory.

What the latest StockTwits stream is actually discussing

• Additional days before an official 80th-event announcement are frequently interpreted by long-biased users as a favorable survival clue.
• Patience and holding common shares into the catalyst remain recurring themes.
• Market-maker and short-positioning explanations are often used to explain intraday weakness.
• The Pomerantz investor alert is generally treated by the long community as a secondary legal headline rather than new clinical information.
• Fatigue is more visible than at the August peak: some users explicitly say they have stopped watching every tick and are simply waiting for the trial milestone.

Important quality warning: tagged-message percentages are useful but are not a clean survey of independent investors. Posts may self-label sentiment inconsistently or discuss multiple tickers.

3. Market feedback: price and sentiment

The late-August alignment between price and social mood is visually striking. On August 21, SLS closed near $15.47 on the IEX series used here while StockTwits sentiment reached 80. By August 28, the IEX close was about $13.17 and the sentiment score was 56. On September 2, price recovered to roughly $14.14 while sentiment stayed in the mid-50s instead of returning to euphoria.

This is descriptive, not causal. Social sentiment, news flow, options activity, short positioning and ordinary market microstructure can all move together. A same-day relationship does not establish that posts caused the stock move.

4. X: a small number of voices can dominate reach

The expanded check found one clearly mainstream, high-profile biotech-media voice discussing SLS in the current window: Adam Feuerstein. STAT identifies Feuerstein as a senior biotech writer and columnist, cohost of The Readout LOUD and part of a team whose Aduhelm coverage won a George Polk Award.

In public X commentary during the current SLS debate, Feuerstein took a critical tone toward the company’s communication cadence, particularly CEO LinkedIn activity during the period described by management as approaching an official quiet period. A representative post was captured by a public X mirror at roughly 22,000 views. That is a measure of reach, not evidence about REGAL efficacy and not a measure of credibility.

Prominence check: in the reviewed window, we did not find comparably prominent current SLS commentary from Brad Loncar, Matthew Herper or Jacob Plieth. No position is attributed to them.

What the two X thesis camps are arguing

BMF Reports: a disclosed short thesis

The August 28 BMF publication matters because it turns the skeptical case into a structured long-form thesis rather than a single social post. BMF explicitly discloses that it is short SLS. Its report challenges the interpretation of the blinded event clock, discusses statistical-power assumptions and valuation, and models a substantially lower share price in a REGAL-failure scenario.

BMF later added an important clarification: the exact powered hazard ratio is not publicly disclosed in the operative protocol, and an approximately 0.484 HR derived from conventional back-solving is an inference, not a disclosed trial parameter. That distinction should be preserved. The report comes from a publisher that explicitly discloses a short position in SLS; it is useful as a map of the short thesis, but it is not an independent clinical adjudication.

5. Reddit, Seeking Alpha, InvestorsHub and TradingView

Reddit: strongly bullish, but the risk warning is explicit

The dedicated SLS subreddit is the clearest long-community concentration in the expanded sample. The September 3 daily thread contains bullish catalyst expectations, position-building comments and squeeze discussion. At the same time, the thread header itself states that SLS is awaiting binary Phase 3 REGAL results, that daily price action is volatile and that successful trial results are not guaranteed.

This combination is useful: the community is strongly bullish, but the platform is not pretending the catalyst is risk-free.

Seeking Alpha: the best visible internal challenge to the bull case

The visible Seeking Alpha SLS comments are noticeably less one-sided. One self-described former pharma professional wrote that they were bullish on SLS while pushing back on extreme buyout estimates, arm-specific inferences from pooled survival and the use of the word “cure.” Other comments remain far more aggressive on targets, while skeptics question whether a multi-billion-dollar valuation already embeds a high probability of success and whether BAT could be contributing to longer survival.

The result is still mixed-bullish in the visible sample, but the quality of internal challenge is higher than in the most dedicated long communities.

InvestorsHub and TradingView: confirmation, but lower weight

InvestorsHub offers a smaller current discussion set. Recent posts focus on the event chronology and often treat the slowing death count as notable while acknowledging administrative lag and the impossibility of identifying which arm drives the tail. The sample is too small to carry the same weight as StockTwits or Reddit.

TradingView’s SLS idea archive skews long in the visible set and contains breakout/uptrend narratives, but freshness is uneven. It is best used as a weak confirmation of trader bias, not as a current sentiment score.

6. Management communication is now part of the sentiment loop

SELLAS CEO Angelos Stergiou has maintained a visible LinkedIn presence. In a post titled “Separating Noise from Data in SELLAS Life Sciences Group, Inc. Phase 3 REGAL Trial”, he wrote that it “may likely” be his last brief REGAL posting before approaching the 80th event and entering an official quiet period until topline.

Subsequent company and pipeline commentary is interpreted differently by different audiences. Some shareholders view direct CEO communication as confidence and transparency; critics view the cadence more skeptically. The only defensible analytical conclusion is narrower: management communication can move sentiment, but it cannot reveal blinded randomized results.

Fresh pipeline narrative: SLS009 in pancreatic cancer

On September 2, SELLAS announced that three SLS009 (tambiciclib) abstracts were accepted for poster presentation at the AACR Conference on Pancreatic Cancer, scheduled for September 25–28 in San Diego. The work uses patient-derived KRAS-mutant organoid models and was conducted with the University of Wisconsin School of Medicine and Public Health.

This expands the public narrative beyond REGAL and first-line AML. But the evidence level is precise: this pancreatic work is preclinical. It does not establish efficacy or safety in patients.

7. Reported short interest: where real capital disagrees

The latest available short-interest settlement in the reviewed dataset is August 14, 2026: 56,371,865 shares sold short, about 28.28% of public float on MarketBeat’s float calculation, with roughly 10.4 days to cover. Reported short interest had exceeded 63 million shares in June, fell in July and then increased modestly by mid-August.

This is a critical complement to social-media sentiment. StockTwits can show more than 90% bullish self-tagged messages while tens of millions of shares remain sold short. The measurements answer different questions: one captures vocal retail mood; the other captures reported bearish positioning.

The Pomerantz alert: an investigation notice, not a finding

On September 3, Pomerantz LLP published another investor alert stating that it is investigating potential claims related to SELLAS following an August 28 report alleging that REGAL had reached the 80th event. The wording matters: an investigation notice is not a court judgment and does not establish that securities fraud occurred.

The alert is relevant to sentiment because it repeats the disputed 80th-event narrative in a legal context. It does not change the verified clinical data state.

8. Fact check: verified facts, inference and unconfirmed claims

9. Platform-by-platform composite read

Composite verdict: SLS is not a 50/50 sentiment story. The public community majority is bullish, while skeptical voices have disproportionate reach and reported short capital remains large. The cleanest description is convicted long-biased retail versus concentrated skepticism around an unresolved binary catalyst.

10. What could change sentiment next

11. Sources and audit trail

The article deliberately links primary sources for clinical and corporate facts and labels commentary as commentary.

Primary / company sources

• SELLAS Q1 2026 corporate update — May 12, 2026 — 78 events as of May 11; company remained blinded; final analysis follows the 80th event.
• SELLAS REGAL interim analysis — Jan. 23, 2025 — IDMC recommended continuation without modification after the 60-event interim analysis.
• SELLAS Q2 2026 results and corporate update — Aug. 11, 2026 — 28 patients in first-line AML, Q4 topline expectation, $138.3M cash.
• SELLAS SLS009 pancreatic AACR announcement — Sep. 2, 2026.
• Angelos Stergiou LinkedIn: “Separating Noise from Data…”.

Market / social / commentary sources

• StockTwits — SLS stream; quantitative pulse and 1-month histories retrieved September 3, 2026.
• STAT — Adam Feuerstein profile · X profile · TickerTalks SLS aggregation for the captured SLS post/reach context.
• BMF Reports — SLS short report, Aug. 28, 2026 (disclosed short position).
• Reddit SLS daily discussion — Sep. 3, 2026.
• Seeking Alpha — SLS comments.
• InvestorsHub — SLS board.
• TradingView — SLS community ideas.
• MarketBeat — SLS short-interest history, using exchange/FINRA-reported short-interest figures.
• Pomerantz investor alert — Sep. 3, 2026.